tetano
Editor, Senior Moderator
Vaccines (Basel)
. 2023 Mar 14;11(3):653.
doi: 10.3390/vaccines11030653.
T-Cell Response and Antibody Production Induced by the COVID-19 Booster Vaccine in Japanese Chronic Kidney Disease Patients Treated with Hemodialysis
Ayumi Yoshifuji[SUP] 1 2 [/SUP], Masataro Toda[SUP] 2 [/SUP], Munekazu Ryuzaki[SUP] 1 2 [/SUP], Emi Oyama[SUP] 1 [/SUP], Kan Kikuchi[SUP] 1 [/SUP], Toru Kawai[SUP] 1 [/SUP], Ken Sakai[SUP] 1 [/SUP], Masayoshi Koinuma[SUP] 3 [/SUP], Kazuhiko Katayama[SUP] 4 [/SUP], Takashi Yokoyama[SUP] 5 [/SUP], Yuki Uehara[SUP] 1 [/SUP], Norio Ohmagari[SUP] 1 [/SUP], Yoshihiko Kanno[SUP] 1 [/SUP], Hirofumi Kon[SUP] 1 [/SUP], Toshio Shinoda[SUP] 1 [/SUP], Yaoko Takano[SUP] 1 [/SUP], Junko Tanaka[SUP] 1 [/SUP], Kazuhiko Hora[SUP] 1 [/SUP], Yasushi Nakazawa[SUP] 1 [/SUP], Naoki Hasegawa[SUP] 1 [/SUP], Norio Hanafusa[SUP] 1 [/SUP], Fumihiko Hinoshita[SUP] 1 [/SUP], Keita Morikane[SUP] 1 [/SUP], Shu Wakino[SUP] 1 [/SUP], Hidetomo Nakamoto[SUP] 1 [/SUP], Yoshiaki Takemoto[SUP] 1 [/SUP]
Affiliations
Abstract
Humoral and cellular responses are critical in understanding immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. Here, we evaluated these responses in hemodialysis (HD) patients after the booster vaccination. SARS-CoV-2 immunoglobulin (IgG) levels, neutralizing antibody titers, and the T-SPOT[SUP]®[/SUP].COVID test (T-SPOT) were measured prior to, three weeks after, and three months after the booster administration. The HD group had significantly higher SARS-CoV-2 IgG levels and neutralizing antibody titers against the original strain at three weeks and three months after the booster vaccination compared to the control group, albeit the HD group had lower SARS-CoV-2 IgG levels and neutralizing antibody titers before the booster administration. Moreover, the HD group had significantly higher T-SPOT levels at all three time points compared to the control group. The HD group also had significantly higher local and systemic adverse reaction rates than the control group. By booster vaccination, HD patients could acquire more effective SARS-CoV-2-specific humoral and cellular immunity than the control group.
Keywords: COVID-19; adverse reactions; cellular immunity; hemodialysis; humoral immunity; vaccination; vaccine.
. 2023 Mar 14;11(3):653.
doi: 10.3390/vaccines11030653.
T-Cell Response and Antibody Production Induced by the COVID-19 Booster Vaccine in Japanese Chronic Kidney Disease Patients Treated with Hemodialysis
Ayumi Yoshifuji[SUP] 1 2 [/SUP], Masataro Toda[SUP] 2 [/SUP], Munekazu Ryuzaki[SUP] 1 2 [/SUP], Emi Oyama[SUP] 1 [/SUP], Kan Kikuchi[SUP] 1 [/SUP], Toru Kawai[SUP] 1 [/SUP], Ken Sakai[SUP] 1 [/SUP], Masayoshi Koinuma[SUP] 3 [/SUP], Kazuhiko Katayama[SUP] 4 [/SUP], Takashi Yokoyama[SUP] 5 [/SUP], Yuki Uehara[SUP] 1 [/SUP], Norio Ohmagari[SUP] 1 [/SUP], Yoshihiko Kanno[SUP] 1 [/SUP], Hirofumi Kon[SUP] 1 [/SUP], Toshio Shinoda[SUP] 1 [/SUP], Yaoko Takano[SUP] 1 [/SUP], Junko Tanaka[SUP] 1 [/SUP], Kazuhiko Hora[SUP] 1 [/SUP], Yasushi Nakazawa[SUP] 1 [/SUP], Naoki Hasegawa[SUP] 1 [/SUP], Norio Hanafusa[SUP] 1 [/SUP], Fumihiko Hinoshita[SUP] 1 [/SUP], Keita Morikane[SUP] 1 [/SUP], Shu Wakino[SUP] 1 [/SUP], Hidetomo Nakamoto[SUP] 1 [/SUP], Yoshiaki Takemoto[SUP] 1 [/SUP]
Affiliations
- PMID: 36992238
- DOI: 10.3390/vaccines11030653
Abstract
Humoral and cellular responses are critical in understanding immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. Here, we evaluated these responses in hemodialysis (HD) patients after the booster vaccination. SARS-CoV-2 immunoglobulin (IgG) levels, neutralizing antibody titers, and the T-SPOT[SUP]®[/SUP].COVID test (T-SPOT) were measured prior to, three weeks after, and three months after the booster administration. The HD group had significantly higher SARS-CoV-2 IgG levels and neutralizing antibody titers against the original strain at three weeks and three months after the booster vaccination compared to the control group, albeit the HD group had lower SARS-CoV-2 IgG levels and neutralizing antibody titers before the booster administration. Moreover, the HD group had significantly higher T-SPOT levels at all three time points compared to the control group. The HD group also had significantly higher local and systemic adverse reaction rates than the control group. By booster vaccination, HD patients could acquire more effective SARS-CoV-2-specific humoral and cellular immunity than the control group.
Keywords: COVID-19; adverse reactions; cellular immunity; hemodialysis; humoral immunity; vaccination; vaccine.